2026-05-22T00:35:36Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231112024-11-28T15:59:34Zcom_20.500.12105_2173com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19597col_20.500.12105_16938

00925njm 22002777a 4500 dc Herrera-Juárez, Mercedes author Serrano-Gómez, Cristina author Bote-de-Cabo, Helena author Paz Ares, Luis Gonzaga author 2023-06-15 Precision oncology comprises the set of strategies that aim to design the best cancer treatment based on tumor biology. A recognized subset of patients with non-small cell lung cancer (NSCLC) harbor actionable genomic aberrations that can benefit from targeted therapy. In lung cancer, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are well characterized oncogenic drivers for which the therapeutic use of tyrosine kinase inhibitors has demonstrated improved outcomes compared with chemotherapy. Other druggable targets are also well characterized, and effective inhibitors have been developed and commercialized, leading to a paradigm shift in NSCLC treatment. Here, the authors provide a review of the oncogenic role of the most relevant molecular alterations in NSCLC and emerging treatments in this setting beyond EGFR-driven and ALK-driven diseases. Cancer . 2023 ;129(12):1803-1820. 10.1002/cncr.34757 1097-0142 Cancer 37073562 https://hdl.handle.net/20.500.12105/23111 Targeted therapy for lung cancer: Beyond EGFR and ALK